Abstract
Immunotherapy has become a standard early line therapy for advanced non-small cell lung cancer (NSCLC). Post-progression sequencing and utilization of subsequent active therapies is of increasing importance and currently lacks expert consensus. Vinorelbine, a member of the vinca alkaloid family, is an active anti-cancer chemotherapy agent in NSCLC that may offer patients clinical benefit in this setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
